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Background: Immunoglobulin A nephropathy (IgAN) is the most common form of glomerulonephritis in China. An
accurate diagnosis of IgAN is dependent on renal biopsies, and there is lack of non-invasive and practical
classification methods for discriminating IgAN from other primary kidney diseases. The objective of this study was
to develop a classification model for the auxiliary diagnosis of IgAN using multiparameter analysis with various
biological parameters.
Methods: To establish an optimal classification model, 121 cases (58 IgAN vs. 63 non-IgAN) were recruited and
statistically analyzed. The model was then validated in another 180 cases.
Results: Of the 57 biological parameters, there were 16 parameters that were significantly different (P< 0.05)
between IgAN and non-IgAN. The combination of fibrinogen, serum immunoglobulin A level, and manifestation
was found to be significant in predicting IgAN. The validation accuracies of the logistic regression and discriminant
analysis models were 77.5 and 77.0%, respectively at a predictive probability cut-off of 0.5, and 81.1 and 79.9%,
respectively, at a predictive probability cut-off of 0.40. When the predicted probability of the equation containing
the combination of fibrinogen, serum IgA level, and manifestation was more than 0.59, a patient had at least an
85.0% probability of having IgAN. When the predicted probability was lower than 0.26, a patient had at least an
88.5% probability of having non-IgAN. The results of the net reclassification improvement certificated serum
Immunoglobulin A and fibrinogen had classification power for discriminating IgAN from non-IgAN.
Conclusions: These models possess potential clinical applications in distinguishing IgAN from other primary kidney
diseases.
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While some nephrologists may administer tentative drugs
to patients with chronic kidney disease (CKD) based on
the clinical manifestation prior to performing a renal bi-
opsy, they still depend on a percutaneous renal biopsy to
make a definite histological diagnosis, and thereby, deter-
mine an efficient drug administration strategy [1-3],
especially for patients with resistance or unresponsiveness
to immunosuppressive agents, anticoagulants, and/or
angiotensin-converting enzyme inhibitor (ACEI) [4-6].* Correspondence: tianyp61@gmail.com
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reproduction in any medium, provided the orHowever, despite the advantages of being safe, simple, and
easy, this invasive procedure is not risk-free [7]. Further-
more, based on our clinical experiences, at times, renal bi-
opsies cannot be performed on certain patients due to
contraindications [8,9], patient refusal, and insufficient op-
erative skills of physicians at certain hospitals. Moreover,
the pathologic diagnosis obtained from renal biopsies may
be variable. It was previously reported that there was a
common change in the histological patterns of lupus
nephritis with repeated renal biopsies [10]. This may be
due to disease progression, different surgeons performing
the biopsy, different biopsy amounts and parts of tissue
obtained, and discordant opinions from different nephro-
pathologists [11,12]. Thus, patients would benefit if there. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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discriminating the pathological subtypes of kidney disease.
It also has been previously reported that mathematical
models may be used to classify different diseases or stages
of diseases [13,14]. In fact, some classification equations
are already being used in kidney disease. In our previous
retrospective study, we reported that the combination of
six serum indicators could discriminate immunoglobulin
A nephropathy (IgAN) from non-immunoglobulin A
nephropathy (non-IgAN) with an 82.3% sensitivity and a
68.6% specificity [15]. This classification method was
found to be efficient in the auxiliary diagnosis of IgAN,
which is still the most common form of glomeruloneph-
ritis in China [16].
In the present study, we utilized common statistical
analyses (including logistic regression and discriminant
analyses) and typical biological parameters to determine




The present study was a retrospective cohort study, was
conducted in accordance with the Declaration of Hel-
sinki, and approved by the Medical Ethics Committee of
the Chinese PLA General Hospital. Patient research con-
sent form was presented as Additional File 1. Fasting
blood samples were collected on the second day after
patients were admitted into our hospital, according to
the established inclusion criteria. Patients were then
screened again, according to established exclusion cri-
teria, and divided into two groups, one for establishing a
classification model (after 2011), and the other for valid-
ating the classification model (before 2011).
Patients
The inclusion criteria were established to pre-screen all
patients. The inclusion criteria were as follows: a) the
patient was admitted into the Division of Nephrology at
our hospital for the first time; b) a renal biopsy had not
been previously performed on the patient for the exact
pathologic diagnosis at our or any other hospital; c) the
patient was not previously undergoing anti-coagulation,
immunosuppression, and/or renal replacement therapy;
d) the patient may present with either hepatitis, diabetes,
hypertension, or lupus, but not with a tumor; and e) the
patient approved to undergo a renal biopsy during the
hospital admission. The exclusion criteria used for the
final selection of cases were as follows: a) if for any rea-
sons the renal biopsy was not preformed on the included
patient (e.g. the patient refused a renal biopsy examin-
ation, the patient’s condition worsened during the period
of admission, the kidneys of the patient were atrophied
or sclerotic.); b) the pathological results indicated thatthe patient has secondary kidney disease, including dia-
betic nephropathy, lupus nephritis, hepatitis-related
nephropathy; and c) the pathological results could not
ascertain whether the patient has primary nephropathy.
Based on the exclusion criteria, 301 cases were selected.
The immunofluorescence findings, exact histopatho-
logical diagnosis for non-IgAN, and Oxford classification
score for IgAN of the 121 patients allocated into the
‘modeling’ group, which was used in establishing the
classification model, are listed in Additional file 2.
Samples and blood tests
Blood samples of all included patients underwent blood
coagulation testing (STA-R automatic coagulation
analyzer, Stago), blood routine examination (Xe-2100
automatic blood analyzer, Sysmex), clinical biochemistry
testing (Roche Modular DDP, Roche), immunoglobulin-
complement testing (BNΙΙ particular globin analyzer, Sie-
mens), and tumor marker testing (Roche Modular E170,
Roche). The remaining sera were preserved at −80 °C.
Biological parameters and data grouping
Besides “manifestation”, the other 56 biological para-
meters were listed in Table 1. Data on all of 57 biological
parameters were collected and divided into two groups,
according to the renal biopsy results: the IgA nephropa-
thy (IgAN) group, which was defined as the presence of
IgA immune complex deposits predominantly within the
mesangial region of the renal glomerulus, and the non-
IgA nephropathy (non-IgAN) group, which was defined
as a lack of IgA immune complexes or the absence of
IgA immune complex deposits predominantly within the
mesangial region of the renal glomerulus. The selected
301 cases were divided into either the ‘modeling’ group
(after 2011) or the ‘validation’ group (before 2011).
Statistic analysis
SPSS 17.0 was used for data analysis. Statistical analyses,
including t-tests, nonparametric tests (i.e. Mann–Whit-
ney U-test), chi-square test and bivariate correlation
tests, were conducted for the selection of different para-
meters. Logistic regression and discriminant analyses
were used in establishing the classification model for
IgAN and non-IgAN.
The net reclassification improvement (NRI) was used




The ‘modeling’ group consisted of 121 cases, including
58 IgAN and 63 non-IgAN cases (average age of
35.6 ± 12.4 and 39.7 ± 15.3 years, respectively). The ‘val-
idation’ group consisted of 180 cases, including 93 IgAN
Table 1 Biological parameters assessed in the present study
Index Full name Abbreviation Reference range
1 Carcinoembryonic antigen CEA 0-5 μg/L
2 Alpha fetoprotein AFP 0-20 μg/L
3 Carbohydrate antigen 125 CA125 0.1-35 u/ml
4 Carbohydrate antigen 199 CA199 0.1-37 u/ml
5 Carbohydrate antigen 153 CA153 0.1-30 u/ml
6 Carbohydrate antigen 724 CA724 0.1-10 u/ml
7 Cytokeratin fragment 21-1 CYFRA21-1 0.1-4 ng/ml
8 Neuron specific enolase NSE 0-24 ng/ml
9 Squamous cell carcinoma
related antigen
SCC 0-1.5 ug/L
10 Glucose Glu 3.4-6.2 mmol/L
11 Total protein TP 55-80 g/L
12 Albumin ALB 35-50 g/L
13 Urea nitrogen UN 1.8-7.5 mmol/L
14 Creatinine Cr 30-110 μmol/L
15 Uric acid Ua 104-444 μmol/L
16 Total cholesterol CH 3.1-5.7 mmol/L







20 Potassium K 3.5-5.5 mmol/L
21 Sodium Na 130-150 mmol/L
22 Calcium Ca 2.25-2.75 mmol/L
23 Chloride Cl 94-110 mmol/L
24 Phosphorus P 0.97-1.62 mmol/L
25 Magnesium Mg 0.6-1.4 mmol/L
26 Carbon dioxide CO2 20.2-30 mmol/L
27 Total bilirubin TB 0-21 μmol/L
28 Direct bilirubin DB 0-8.6 μmol/L
29 Alanine aminotransferase ALT 0-40 U/L
30 Aspartate aminotransferase AST 0-40 U/L
31 Lactate dehydrogenase LDH 40-250 U/L
32 Creatine kinase CK 2-200 U/L
33 γ-Glutamyltransferase GGT 0-50 U/L
34 Alkaline phosphatase ALP 0-130 U/L
35 International normalized ratioINR 0.8-1.2
36 Fibrinogen FIB 2.0-4.0 g/L
37 Prothrombin time PT 11.0-15.0 s
38 Prothrombin activity PA 70-120%
39 Activated coagulation
time of whole blood
APTT 30-45 s
40 D-dimer D2 0.0-0.5 μg/L
41 β2-microglobulin B2MG 0.07-0.18 mg/dl
42 Serum immunoglobulin A sIgA 70-180 mg/dl
Table 1 Biological parameters assessed in the present study
(Continued)
43 Serum immunoglobulin G sIgG 700-1600 mg/dl
44 Serum immunoglobulin E sIgE 0-100 IU/ml
45 Serum immunoglobulin M sIgM 40-230 mg/dl
46 Complement 3 C3 90-180 mg/dl
47 Complement 4 C4 10-40 mg/dl
48 Prealbumin PA 20-40 mg/dl
49 Red blood count RBC Male:4.3-5.9 * 1012/L
Female: 3.9-5.2 * 1012/L
50 Hemoglobin HB Male: 137-179 g/L
Female: 116-155 g/L
51 White blood count WBC 3.5-10 * 109/L
52 Platelet PLT 100-300 * 109/L
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43.7 ± 15.7 years, respectively). Patient characteristics of
the ‘modeling’ and ‘validation’ groups are presented in
Table 2.
Univariate analysis
T- and Mann–Whitney U-tests were performed to deter-
mine significant differences in all of the 57 parameters
studied between the IgAN and non-IgAN groups. The
mean ± SD, median with extremes, and the P-values are
presented in Additional file 3. Besides manifestation,
there were 15 serological indicators that were signifi-
cantly different (P< 0.05) between IgAN and non-IgAN
(Table 3). Some of these parameters, including serum fi-
brinogen (FIB), serum D-dimer (D2), serum immuno-
globulin A (sIgA), serum immunoglobulin G (sIgG),
serum albumin (ALB), serum total protein (TP), serum
total cholesterol (CH), serum low density lipoprotein
(LDL), serum triglyceride (TG), and serum urea (UN),
have been previously implicated in kidney disease [17].
However, serum direct bilirubin (DB), serum calcium
(Ca), serum alkaline phosphatase (ALP), serum carbohy-
drate antigen 19–9 (CA199), and serum carbohydrate
antigen 15–3 (CA153) have never been implicated in
kidney disease.
Receiver operating characteristics (ROC) curve ana-
lyses were performed on these 57 parameters, and the
findings (i.e. area under curve (AUC), 95% confidence
interval (CI) and P-value) were presented in Additional
file 4. Table 4 contained the C statistics of 16
Table 3 Differences in the serological parameters
between IgAN and non-IgAN
Parameter Mean±SD P-value
IgAN Non-IgAN
FIBa 3.63 ± 1.00 5.00 ± 2.60 0.000
sIgGa 1018.5 ± 307.0 858.2 ± 352.7 0.020
TP b 66.2 ± 9.5 57.3 ± 12.7 0.000
ALB b 39.1 ± 6.5 31.7 ± 9.7 0.000
Ca b 2.22 ± 0.15 2.09 ± 0.18 0.000
D2a 0.70 ± 1.26 1.46 ± 2.99 0.019
sIgA a 331.3 ± 103.9 241.5 ± 102.3 0.000
CHa 4.84 ± 1.24 6.38 ± 2.79 0.002
DBa 3.1 ± 1.8 2.4 ± 1.3 0.029
LDLa 2.98 ± 1.00 4.14 ± 2.23 0.003
CA153a 11.9 ± 5.2 14.9 ± 7.7 0.038
TGa 1.7 ± 1.1 2.1 ± 1.0 0.013
ALPa 68.8 ± 40.2 81.0 ± 50.3 0.015
CA199a 12.0 ± 8.7 18.8 ± 20.3 0.046
UN a 6.6 ± 3.1 6.1 ± 3.4 0.048
aP< 0.05 via Mann–Whitney U-test; b P< 0.05 via t-test
Abbreviations: FIB, fibrinogen; sIgG, serum immunoglobulin G; TP, total
protein; ALB, albumin; Ca, calcium; D2, D-dimer; sIgA, serum immunoglobulin
A; CH, total cholesterol; DB, direct bilirubin; LDL, low density lipoprotein;
CA153, carbohydrate antigen 15–3; TG, triglyceride; ALP, alkaline phosphatase;
CA199, carbohydrate antigen; UN, urea.
Table 2 Patients characteristics of the modeling and
validation groups
Modeling group Validation group
IgAN Non-IgAN IgAN Non-IgAN
Number 58 63 93 87
Age (years) 35.6 ± 12.4 39.7 ± 15.3 32.8 ± 11.6 b 43.7 ± 15.7 b
Male : female 39:19 33:30 53:40 48:39
Hypertension (%) 28 (48.3%) 28 (44.4%) 45 (48.9%) 50 (57.5%)
Body mass
index (kg/m2)




44 (75.9%)a 23 (36.5%)a 75 (80.6%)a 31 (35.6%)a
Nephrotic
syndrome (%)
10 (17.2%)a 33 (52.4%)a 10 (10.8%)a 51 (58.6%)a
Isolated proteinuria
or hematuria (%)
4 (6.9%)a 7 (11.1%)a 8 (8.6%)a 5 (5.7%)a
Renal function
Normal (%) 43 (74.1%) 48 (76.2%) 67 (72.0%) 69 (79.3%)
Chronic renal
insufficiency (%)
15 (25.9%) 11 (17.5%) 25 (26.9%) 14 (16.1%)
Acute renal
insufficiency (%)
0 4 (6.3%) 1 (1.1%) 4 (4.6%)
a P< 0.05 via Chi-square test, between IgAN and Non-IgAN; b P< 0.05 via t-test,
between IgAN and Non-IgAN.
Notes: Hypertension was defined as systolic blood pressure (BP) ≥140 mmHg,
diastolic BP ≥90 mmHg, or use of antihypertensive medications. Chronic
nephritis syndrome was defined as proteinuria or hematuria with hypertension
or edema. Nephrotic syndrome was defined as persistent proteinuria of more
than 3.5 g/1.73 m2/24 h, hypoalbuminemia or albumin levels ≤30 g/L, edema,
and varying degrees of hyperlipidemia. Isolated proteinuria or hematuria was
defined as a urine protein excretion >0.3 g/1.73 m2/24 h or urine red blood
cell (RBC) >3/HP with normal renal function and without hypertension and
edema. Normal renal function was defined as estimated glomerular filtration
rate (GFR) >90 ml/min/1.73 m2 on at least two occasions. Chronic renal
insufficiency was defined as an estimated GFR <60 ml/min/1.73 m2 on at least
two occasions with chronic kidney disease. Acute renal insufficiency was
defined as an abrupt (within 48 h) reduction in kidney function, according to
the Acute Kidney Injury Network (AKIN) criteria.
Abbreviations: IgAN, Immunoglobulin A nephropathy; Non-IgAN, non-
immunoglobulin A nephropathy.
Table 4 C statistics of the ROC curves for the 16 significant
parameters between IgAN and non-IgAN
Parameter AUC 95% Confidence lnterval P-value
lower Bound upper Bound
CA199 b 0.605 0.505 0.706 0.046
CA153 b 0.609 0.509 0.709 0.038
TP a 0.703 0.611 0.796 0.000
ALB a 0.727 0.636 0.819 0.000
UN a 0.604 0.503 0.706 0.048
CH b 0.667 0.572 0.763 0.002
TG b 0.631 0.532 0.731 0.013
LDL b 0.657 0.560 0.753 0.003
Ca a 0.718 0.625 0.810 0.000
Cl b 0.628 0.528 0.729 0.015
DB a 0.615 0.514 0.717 0.029
ALP b 0.628 0.528 0.729 0.015
FIB b 0.712 0.621 0.804 0.000
D2 b 0.626 0.525 0.727 0.019
sIgA a 0.756 0.670 0.842 0.000
sIgG a 0.623 0.524 0.722 0.020
Abbreviations: CA199, carbohydrate antigen; CA153, carbohydrate antigen 15–3;
TP, total protein; ALB, albumin; UN, urea; CH, total cholesterol; TG, triglyceride; LDL,
low density lipoprotein; Ca, calcium; Cl, chloride; DB, direct bilirubin; ALP, alkaline
phosphatase; FIB, fibrinogen; D2, D-dimer; sIgA, serum immunoglobulin A; sIgG,
serum immunoglobulin G.
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which five parameters, specifically TP, ALB, Ca, FIB, and
sIgA, with the additional manifestation were highly sig-
nificant variables (P< 0.01). sIgA, ALB, and Ca had the
top three diagnostic levels (i.e. 75.6, 72.7, and 71.8%) be-
tween IgAN and non-IgAN (Figure 1).
Based on the findings of the t- or U-tests and ROC curve
analyses, 16 parameters, including manifestation, sIgA,
sIgG, D2, TP, ALB, CH, TG, LDL, UN, DB, Ca, ALP,
CA199, and CA153, were selected for further analysis.
Correlation analysis of pre-selected parameters
Multiple correlations were found among biological para-
meters or medical data. However, multiparameter analysis
requires that each explanatory variable is independent.
Thus, bivariate correlation tests were executed to
Figure 1 Respective ROC Curve of sIgA, ALB and Ca between IgAN
and non-IgAN. ROC curves for serum immunoglobulin A level (sIgA),
ALB (albumin) and Ca (calcium) in immunoglobulin A nephropathy
(IgAN) and non-immunoglobulin A nephropathy (non-IgAN) patients.
The state variable is IgAN.
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performing multiparameter analysis. It was found that
there were significant correlations (P< 0.01) among al-
most half of the 16 parameters, specifically among “mani-
festation”, FIB, sIgG, TP, ALB, CH, LDL, and Ca
(Figure 2). Based on our clinical experience, we removedFigure 2 Correlation coefficients between two variables of pre-selecteTP, LDL, and Ca, and selected the other 13 parameters for
further analysis.
Modeling with multiparameter analysis
Logistic regression and discriminant analyses were used
to establish the IgAN and non-IgAN classification
model. The 13 pre-selected parameters were manifest-
ation, FIB, D2, sIgA, sIgG, ALB, UN, CH, TG, DB, ALP,
CA199, and CA153.
a) Model based on logistic regression analysis: Except
manifestation, the other 12 pre-selected parameters were
substituted into a binary logistic regression as an ex-
planatory variable via the “Enter” method of a univariate
analysis (Table 5). Parameters that had a P< 0.2 in uni-
variate logistic regression were chosen to prevent the ex-
clusion of important variables. With the exception of
UN, the other 12 variables had a P< 0.2 and were all
substituted into the multivariate logistic regression,
using the forward conditional method of entry. The pre-
dicted probabilities (PRE-1) were calculated and saved.
Using multivariate logistic regression analysis, it was
found that only manifestation, FIB, and sIgA were sig-
nificant predictors of IgAN (Table 6). The classification
model with these 3 parameters was evaluated, and it was
found that accuracy was 76.9%, sensitivity was 74.1%,
specificity was 79.4%, false positive rate (α) was 20.6%,
false negative rate (β) was 25.9%, positive predictive
value (PPV) was 76.8%, negative predictive value (NPV)
was 76.9%, positive likelihood ratio (+LR) was 3.59,d variables.
Figure 3 Figure 3 Area under ROC curve of the predicted
probability of IgAN with “FIB + sIgA+Manifestation”
combination from logistic regression. Area under the ROC curve
for predicting immunoglobulin A nephropathy (IgAN) with the
equation derived via logistic regression analysis, which includes the
“fibrinogen (FIB) + serum immunoglobulin A level
(sIgA) +manifestation” combination. The state variable is IgAN.
Table 7 Parameters used in the discriminant analysis for
developing the classification model
Variables in the analysis
Step Tolerance Sig. of F to Remove Wilks' Lambda
1 ALB 1.000 0.000
2 ALB 1.000 0.000 0.839
Table 5 Univariate logistic regression analysis of the 12
pre-selected serological parameters
Parameter B S.E. Wald df Sig. Exp(B)
FIB 2.485 0.735 11.432 1 0.001 0.534
D2 −0.242 0.161 2.275 1 0.132 0.785
sIgA 0.009 0.002 16.440 1 0.000 1.009
sIgG 0.001 0.001 6.396 1 0.011 1.001
UN 0.049 0.057 0.740 1 0.390 1.051
ALB 0.109 0.026 17.498 1 0.000 1.115
TG −0.326 0.186 3.068 1 0.080 0.722
CH −0.429 0.131 10.673 1 0.001 0.651
DB 0.308 0.126 5.970 1 0.015 1.361
ALP −0.007 0.005 1.883 1 0.170 0.993
CA199 −0.041 0.019 4.855 1 0.028 0.960
CA153 −0.071 0.031 5.293 1 0.021 0.931
Abbreviations: FIB, fibrinogen; D2, D-dimer; sIgA, serum immunoglobulin A;
sIgG, serum immunoglobulin G; UN, urea; ALB, albumin; TG, triglyceride; CH,
total cholesterol; DB, direct bilirubin; ALP, alkaline phosphatase; CA199,
carbohydrate antigen; CA153, carbohydrate antigen 15–3.
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index was 0.535. The area under the ROC curve with
PRE-1 for IgAN was 83.8% (P< 0.0001, 95%CI: 0.766-
0.910) (Figure 3).
The “FIB + sIgA+Manifestation” combination was sig-
nificant in the classification of IgAN and non-IgAN, as
determined via logistic regression analysis. The classifi-
cation equation, which includes these 3 parameters, for
predicting IgAN is as follows:
PRE 1 ¼ 1 1
1þ e 0:6480:326FIBþ0:011sIgA1:089Manifestationð Þ½ 
b) Model based on discriminant analysis: The 13 pre-
selected parameters were substituted into a step discrim-
inant analysis. The predicted probabilities (PRE-2) were
calculated and saved. Similar to the logistic regression
analysis, only sIgA, manifestation, and FIB were signifi-
cant in the classification of IgAN and non-IgAN
(Table 7). The classification model with these 3 para-
meters was evaluated, and it was found that accuracyTable 6 Parameters used in the multivariate logistic
regression analysis for developing the classification model
Parameter B S.E. Wald df Sig. Exp
(B)
95% CI for EXP(B)
Lower Upper
Manifestation −1.089 0.423 6.637 1 0.010 0.336 0.147 0.771
FIB −0.326 0.165 3.918 1 0.048 0.722 0.522 0.997
sIgA 0.011 0.003 16.724 1 0.000 1.011 1.006 1.016
Constant −0.648 0.858 0.569 1 0.450 0.523
Abbreviations: FIB, fibrinogen; sIgA, serum immunoglobulin A.was 76.9%, sensitivity was 79.3%, specificity was 74.6%,
false positive rate (α) was 25.4%, false negative rate (β)
was 20.7%, positive predictive value (PPV) was 74.2%,
negative predictive value (NPV) was 79.7%, positive like-
lihood ratio (+LR) was 3.12, negative likelihood ratio
(−LR) was 0.28, and Youden's index was 0.461. ThesIgA 1.000 0.000 0.834
3 ALB 0.601 0.123 0.702
sIgA 0.974 0.000 0.810
Manifestation 0.593 0.020 0.722
4 sIgA 0.986 0.000 0.846
Manifestation 0.986 0.000 0.839
5 sIgA 0.967 0.000 0.829
Manifestation 0.803 0.003 0.733
FIB 0.789 0.045 0.702
Abbreviations: ALB, albumin; sIgA, serum immunoglobulin A; FIB, fibrinogen.
Figure 4 Area under ROC curve of the predicted probability of
IgAN with “FIB + sIgA+Manifestation” combination from
discriminant analysis. Area under the ROC curve for predicting
immunoglobulin A nephropathy (IgAN) with the equation derived
via discriminant analysis, which includes the “fibrinogen (FIB) + serum
immunoglobulin A level (sIgA) +manifestation” combination. The






























Figure 5 Misdiagnosis rates of the two models with different
cut-offs for the predicted probability.
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83.5% (P< 0.0001, 95%CI: 0.762-0.909) (Figure 4).
The classification equation, which includes the com-
bination of “sIgA+Manifestation + FIB” for predicting
IgAN, is as follows:
PRE 2 ¼ e 1:2234Manifestationþ0:028sIgAþ0:463FIB6:896ð Þ
e 1:2234Manifestationþ0:028sIgAþ0:463FIB6:896ð Þ½
þe 2:452Manifestationþ0:018sIgAþ0:713FIB6:371ð ÞTable 8 Comparison of the diagnostic efficiency of the two m


















Abbreviations: IgAN, immunoglobulin A nephropathy; Non-IgAN, non-immunoglobuValidation of the two models
One-hundred and eighty new cases were substituted into
the two equations of PRE-1 and PRE-2. Each predicted
probability was calculated and compared with the biopsy
diagnosis. The sensitivity and specificity were compared
between the different cut-off points of predicted prob-
abilities (Table 8). When the cut-off point of the
predicted probabilities was decreased to 0.40, the sensi-
tivities of the two models increased, whereas the specifi-
cities decreased. When the cut-off point of the predicted
probabilities was 0.40, the frequency of misdiagnosis of
the two models was higher between 0.26-0.59 than for
<0.26 and >0.59 (Figure 5). This indicates that when we
use a mathematical model for predicting a clinical diag-
nosis, we have to pay close attention to the cases near
the cut-off points of the predicted probabilities, as they
are prone to misdiagnosis. Further analysis indicated
that, when the predicted probability is >0.59 or <0.26,odels for predicting IgAN and non-IgAN
iopsy diagnosis Sensitivity Specificity Accuracy
gAN Non-IgAN
4 12 68.8% 86.2% 77.5%
9 75
7 18 82.8% 79.3% 81.1%
6 69
4 13 68.8% 85.1% 77.0%
9 74
7 20 82.8% 77.0% 79.9%
6 67
lin A nephropathy; PRE, predicted probability.
Table 9 Diagnostic efficiency of the two models when the




IgAN Non-IgAN Sensitivity Specificity
Logistic regression model PRE-1
IgAN 54 7 85.7% 88.5%
Non-IgAN 9 54
Discriminant analysis model PRE-2
IgAN 51 6 85.0% 90.0%
Non-IgAN 9 54
Abbreviations: IgAN, immunoglobulin A nephropathy; non-IgAN, non-
immunoglobulin A nephropathy; PRE, Predicted probability.
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having IgAN or non-IgAN, respectively (Table 9).
Analysis of the net reclassification improvement (NRI)
A logistic regression model and a discriminant analysis
model were made as two primary models with the para-
meters of “gender” and “manifestation”. The 12 pre-
selected biological parameters (sIgA, ALB, FIB, CH, TG,
ALP, D2, sIgG, DB, CA153, CA199 and UN) were put
into the algorithm of the net reclassification improve-
ment (NRI) for assessing the classification power be-
tween IgAN and non-IgAN. According to above results,
we set the predicted probability into four categories:
0 ~ 0.26, 0.26 ~ 0.4, 0.4 ~ 0.59 and 0.59 ~ 1. First, make
gender and manifestation into the original parameters of
the models. Next, add the other 12 parameters one byTable 10 Net reclassification improvement of the 12 pre-
selected biological parameters




NRI P-value NRI P-value
1 sIgA 0.290 0.001 0.308 0.000
2 ALB 0.023 0.157 0.000 –
3 FIB 0.168 0.003 0.169 0.001
4 CH -0.022 0.334 -0.034 0.184
5 TG -0.108 0.037 -0.130 0.017
6 ALP -0.012 0.762 0.019 0.640
7 D2 -0.011 0.317 0.011 0.581
8 sIgG -0.022 0.726 0.003 0.962
9 DB 0.022 0.157 -0.011 0.646
10 CA153 0.001 0.985 -0.022 0.593
11 CA199 -0.011 0.317 0.011 0.775
12 sUN -0.024 0.384 0.022 0.334
Abbreviations: NRI, net reclassification improvement; sIgA, serum immunoglobulin
A; ALB, albumin; FIB, fibrinogen; CH, total cholesterol; TG, triglyceride; ALP, alkaline
phosphatase; D2, D-dimer; sIgG, serum immunoglobulin G; DB, direct bilirubin;
CA153, carbohydrate antigen 15–3; CA199, carbohydrate antigen; UN, urea.one in order of the significance (Table 4) and then check
the NRI and P value. The results showed that only sIgA
and FIB significantly improved the performance of the
models. The NRI of sIgA and FIB was 0.290 and 0.168
(P< 0.005) in the linear logistic regression model,
and was 0.308 and 0.169 (P< 0.005) in the linear dis-
criminant analysis model (Table 10). Each step of adding
the 12 parameters into the basic models were listed in
Additional file 5.
Decision procedure
The decision procedure for the diagnosis of IgA nephro-
pathy in patients with suspected kidney disease, which is
based on the validation dataset and the equation from
the discriminant analysis, is presented in (Figure 6).
Discussion
When statistics are used to determine the significant
predictors for a diagnosis or classification of a disease,
different statistical algorithms, biological datasets, and
parameters may result in different outputs [18-20]. Fur-
thermore, multicollinearity is almost always present with
medical laboratory parameters, which may also bring
out variability and instability in a statistical model [21].
Thus, choosing appropriate variables for multiparameter
analysis is very important.
The present study was designed as a cohort study, and
was based on a previous retrospective study [15]. Com-
pared with the previous study, this study had more para-
meters, including fibrinogen, D-dimer, serum IgA, and
complement C3, all of which are known biomarkers of
kidney diseases [22,23]. Based on univariate analysis,
correlation analysis, and clinical experience, 13 out of 57
routine and useful parameters were selected as predic-
tors of IgAN. These were as follows: manifestation, FIB,
D2, sIgA, sIgG, UN, ALB, TG, CH, DB, ALP, CA199,
and CA153. Three indicators, specifically TP, LDL, and
Ca, were screened out, as they demonstrated the highest
correlations with the other two indicators (correlation
coefficients: TP/ALB= 0.936, LDL/CH=0.968 and Ca/
ALB= 0.813). Similar results were obtained with two of
the most frequently-used multiparameter analyses, in
particular logistic regression and discriminant analyses,
indicating that these three parameters are truly signifi-
cant in classifying IgAN and non-IgAN.
Furthermore, 180 new cases were used to validate the
two equations derived equations for classifying IgAN.
The discerning power of the two classification equations
was similar in the validation cases. The different cut-off
points of the predicted probabilities resulted in different
diagnostic efficiencies, indicating that the cases near the
cut-off point require more attention. Further analysis
indicated that the misdiagnosis rate of cases with pre-
dicted probabilities between 0.26-0.59 was higher than
Patients 
Predicted probabilities 
for the equation derived from 
discriminant analysis
>0.59 0.26-0.59 
85.0% probability  
IgA nephropathy 
Require a renal biopsy and 
histological examination 
<0.26 
90.0% probability  
Non-IgA nephropathy 
Figure 6 Decision procedure for the diagnosis of immunoglobulin A (IgA) and non-IgA nephropathy in patients with suspected kidney
disease.
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(the cut-off point = 0.4). These results are very interest-
ing and important, as: a) if the predicted probability of a
patient is between 0.26-0.59, then the patient needs
more testing for diagnosis, such as a renal biopsy; b) if
the predicted probability of a patient is >0.59, then the
patient has at least an 85.0% possibility of IgAN; and c)
if the predicted probability of a patient is <0.26, then
the patient has at least an 88.5% possibility of non-IgAN.
The net reclassification improvement (NRI), produced
by Penica et al., is used for evaluating the classification
improvement when a new marker is put into a primary
model [24]. For further investigating the classification
power of the pre-selected biological parameters, we used
“gender” and “manifestation” to create a basic linear lo-
gistic regression model and a linear discriminant analysis
model. The results of NRI indicated only sIgA and FIB
were positive for discriminating IgAN from non-IgAN in
this dataset (Table 10).
The exact pathogenesis of IgAN has not been elucidated
up to now. Aberrant IgA1 molecular with the glycans (gal-
actose or sialic acid) deficiencies in the hinge region in cir-
culation is deemed generally to be a crucial and initial
factor for the development and pathological characteristics
of IgAN [25-28]. The previous reports indicated that ab-
normally glycosylated IgA1 molecular had more affinity
with the specific IgA1 receptor in the mesangial cells [29],
was apt to deposit in kidneys combined with circulating
IgG molecular or self-assembled macromolecular [30,31],
and was hard to clear by liver [32]. Since IgA1 is a pre-
dominant isotype of IgA in circulation [33], serum IgAlevel could reflect serum IgA1 level. Some reports showed
that patients with IgAN had elevated serum IgA levels,
and consequently, it might be used as a potential diagnos-
tic marker for IgAN [34,35]. Nevertheless, the method by
using varying degrees of serum IgA level to make a differ-
ential diagnosis for discriminating IgAN from other sub-
types of kidney disease is not widely accepted. The present
study indicated serum IgA level elevated in patients with
both IgAN (331.3± 103.9 mg/dl) and non-IgAN
(241.5± 102.3 mg/dl) according to the reference range
70~180 mg/dl (Table 1). Serum IgA, seemed like not a
specific marker for IgAN, still had significant difference
and differentially diagnostic value (area under curve of
ROC curve: 75.6%, P< 0.0001), which corroborated the
views of some previously study [23].
When serum IgA was combined with the other 2 para-
meters, particularly manifestation and fibrinogen, the
diagnostic accuracy of serum IgA increased from 75.6 to
83.9%, as determined by ROC curve analysis, suggesting
that, with the exception of serum IgA, clotting mechan-
isms might be different in the development of IgAN and
non-IgAN, which reflected in the proportion of neph-
rotic syndrome in IgAN (17.2%) and non-IgAN (52.4%).
To be precise, serum IgA was a relatively specific marker
for IgAN, however fibrinogen and manifestation were
two relatively specific markers for non-IgAN. In 63 non-
IgAN of the modeling group, 55.6% patients were with
membranous nephropathy or minor change disease
(Additional file 1). Nephrotic syndrome is the most
common clinical manifestation of these two subtypes of
glomerular disease [36]. Patients with nephrotic
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hyperfibrinolysis [37,38], which could be caused by the
increased synthesis of blood coagulation factors in liver,
the increased consumption of antithrombin, and the
decreased levels of protein S, protein C and plasminogen
[39,40]. Therefore, as Factor I, serum fibrinogen level
was higher in non-IgAN characterized by the predomin-
ance of nephrotic syndrome than in IgAN, and accord-
ingly had discerning power between the two groups, as
well as D-dimer.
Other significantly different biological parameters be-
tween IgAN and non-IgAN, such as TP, ALB, CH, TG,
LDL and sIgG, were also linked to the different proportion
of nephrotic syndrome (Table 2), which is characterized by
mass proteinuria, hypoalbuminemia, edema, and varying
degrees of hyperlipidemia [36]. Moreover, given that Ca
combines with ALB in blood [41], non-IgAN patients that
appeared to have nephrotic syndrome demonstrated
decreases in serum levels of Ca after a decrease in ALB.
This was confirmed by the high correlation coefficient be-
tween Ca and ALB (0.813) in our analysis.
Furthermore, though DB was significantly different be-
tween IgAN and non-IgAN, the disparity of the averages
was little (3.1 ± 1.8 μmol/L vs. 2.4 ± 1.3 μmol/L), and DB
levels in most patients were normal. It is reported serum
DB correlated with estimated glomerular filtration rate
(eGFR) [42], however, we did not find this correlation
with eGFR calculated by the CKD-EPI equation [43]
(P= 0.35, correlation coefficient = 0.086) in this study.
So, we believed the difference of DB between IgAN and
non-IgAN had no clinical significance.
We have carried out a study for analyzing the clinical
significance of serum CA125 and CA199 levels and their
correlation factors in patients with chronic nephropathy,
and the results indicated when patients with chronic
nephropathy complicated with serous effusions or other
factors favoring the formation of serous effusions, such as
nephrotic syndrome, serum levels of CA125 and CA199
were apt to increase [44]. And CA153 were also correlated
with ALB (correlation coefficient =−0.436, P< 0.0001),
CH (correlation coefficient= 0.451, P< 0.0001), nephrotic
syndrome (correlation coefficient = 0.418, P< 0.0001), FIB
(correlation coefficient= 0.393, P< 0.0001) and LDL (cor-
relation coefficient= 0.440, P< 0.0001). Thus, these two
parameters having significant difference between IgAN
and non-IgAN could also due to the different proportion
of nephrotic syndrome.
Conclusions
In the present study, we report on 3 parameters and 2
classification equations that can be used for discriminat-
ing between IgAN and non-IgAN with more than 79.9%
accuracy. More importantly, when the predicted prob-
ability is more than 0.59, a patient has at least an 85.0%probability of having IgAN. However, when the pre-
dicted probability is below 0.26, a patient has at least an
88.5% probability of having non-IgAN. These equations
may have clinical applicability and value in diagnosing
IgAN, and are based on multiparameter analyses with
various relevant biological parameters.
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